![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with...
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor ► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), Long Island City (New York, Etats-Unis), le 19 juillet 2024 – Inventiva (Euronext...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA...
Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net sales of lanifibranor in the United States of...
Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros Certificats de royalties souscrits par Samsara BioCapital et des actionnaires existants...
Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr Le recrutement dans l'essai clinique de phase III NATiV3 se...
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris...
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.255 | -10.2 | 2.5 | 2.56 | 2.2 | 29169 | 2.345296 | DE |
4 | -0.655 | -22.5862068966 | 2.9 | 2.9 | 2.08 | 47917 | 2.46193042 | DE |
12 | -0.775 | -25.6622516556 | 3.02 | 3.67 | 2.08 | 40660 | 2.87748018 | DE |
26 | -1.255 | -35.8571428571 | 3.5 | 4.3 | 2.08 | 52326 | 3.16809101 | DE |
52 | -1.16 | -34.0675477239 | 3.405 | 4.55 | 2.08 | 55207 | 3.46891101 | DE |
156 | -9.815 | -81.3847429519 | 12.06 | 13.18 | 1.88 | 53052 | 4.66804222 | DE |
260 | 0.38 | 20.3753351206 | 1.865 | 16.3 | 1.54 | 65827 | 6.93467016 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions